Novo Nordisk second best science employer in the world

Novo NordiskNovo Nordisk ranked second in the 2014 Science Careers Top Employers Survey, which is a big jump up the list from last year's ranking where Novo Nordisk came in at number 11. The key drivers of the ranking were the categories 'Treats employees with respect', 'Has loyal employees' and 'Is socially responsible'.

"We're really proud of being ranked number two this year on the prestigious list of the world's best science employers," said Mads Krogsgaard Thomsen, chief science officer and executive vice president at Novo Nordisk. "Our researchers around the world are doing a tremendous job of discussing and developing truly innovative and patient-focused products. The fact that the research community feels that Novo Nordisk is one of the very best places to work matters a great deal for a company growing at Novo Nordisk's pace."

Today Novo Nordisk employs more than 40,000 people globally - a number the company anticipates will rise to more than 60,000 over the next decade. Novo Nordisk Research and Development is a global organisation with more than 6,000 employees working at sites in Denmark, China, US and India.

Novo Nordisk has more than 90 years of experience as a science-driven company with a strong commitment to patients.

"We combine scientific, pharmaceutical and clinical expertise with high ethical standards to continue to improve the quality of life of people living with chronic diseases. As the global leader in diabetes care, millions of people worldwide rely on us to deliver treatments for their disease every day. Additionally, we continue to invest in developing innovative treatments for obesity, haemophilia and growth disorders," says Mads Krogsgaard Thomsen.

The 2014 Science Careers Top Employers Survey is based on 5,394 responses from readers of Science and from employees in the biotechnology and pharmaceutical industry, who were asked to rank the 20 best employers on a number of characteristics.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]